Antoine Bertolotti

Dr. Antoine Bertolotti


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2017 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
ABAntoine Bertolotti
Antoine Bertolotti
Nicolas DupinNicolas Dupin
Nicolas Dupin
FBFabrice Bouscarat
Fabrice Bouscarat
BMBrigitte Milpied
Brigitte Milpied
CDChristian Derancourt
Christian Derancourt

12 March 2020 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
ABAntoine Bertolotti
Antoine Bertolotti
MTMarême Thioune
Marême Thioune
SASylvie Abel
Sylvie Abel
GBGilda Belrose
Gilda Belrose
ICIsabelle Calmont
Isabelle Calmont
TMthe Chronic Chikungunya working group of University Medical Center of Martinique
the Chronic Chikungunya working group of University Medical Center of Martinique
The chikungunya virus (CHIKV) is a re-emerging alphavirus that can cause chronic and potentially incapacitating rheumatic musculoskeletal disorders known as chronic chikungunya arthritis (CCA). We conducted a prospective cohort study of CHIKV-infected subjects during the 2013 chikungunya outbreak in Martinique. The aim of this study was to assess the prevalence of CCA at 12 months and to search for acute phase factors significantly associated with chronicity. A total of 193 patients who tested positive for CHIKV RNA via qRT-PCR underwent clinical investigations in the acute phase (<21 days), and then 3, 6, and 12 months after inclusion. The Asian lineage was identified as the circulating genotype. A total of 167 participants were classified as either with or without CCA, and were analyzed using logistic regression models. The overall prevalence of CCA at 12 months was 52.1% (95%CI: 44.5–59.7). In univariate analysis, age (RD 9.62, 95% CI, 4.87;14.38, p<0.0001), female sex (RD 15.5, 95% CI, 1.03;30.0, p = 0.04), headache (RD 15.42, 95% CI, 0.65;30.18 p = 0.04), vertigo (RD 15.33, 95% CI, 1.47;29.19, p = 0.03), vomiting (RD 12.89, 95% CI, 1.54;24.24, p = 0.03), dyspnea (RD 13.53, 95% CI, 0.73;26.33, p = 0.04), intravenous rehydration (RD -16.12, 95% CI, -31.58; -0.66 p = 0.04) and urea (RD 0.66, 95% CI, 0.12;1.20, p = 0.02) were significantly associated with the development of CCA. For the subpopulation with data on joint involvement in the acute phase, the risk factors significantly associated with CCA were at least one 1 enthesitis (RD 16.7, 95%CI, 2.8; 30.7, p = 0.02) and at least one tenosynovitis (RD 16.8, 95% CI, 1.4–32.2, p = 0.04). This cohort study conducted in Martinique confirms that CCA is a common complication of acute chikungunya disease. Our analysis emphasized the importance of age and female sex for CCA occurrence, and highlighted the aggravating role of dehydration during the acute phase. Early and adequate hydration were found to reduce the risk chronic chikungunya disorders. clinicaltrials.gov (NCT01099852). Chikungunya is a tropical, mosquito-borne virus that has been re-emerging in the last decade. It has caused major epidemics in recent years, including in Reunion Island and in Southeast Asia. Nearly 2.5 billion people around the world are at risk of contracting the virus. In the acute phase of the illness, patients experience a flu-like syndrome with fever, headache, myalgia, rash, and severe arthralgia. These symptoms can persist for several months in some patients, and can lead to significant functional disability. During the 2013 epidemic in Martinique, we followed nearly 200 patients who had contracted chikungunya. More than half of the patients had a chronic form of the disease—mainly women over 50 years of age. Our statistical analyses indicate that poor hydration in the acute phase is a risk factor for developing chronic rheumatism. This suggests that, in the context of a chikungunya epidemic, patients should drink plenty of fluids as soon as the first symptoms appear.

5 December 2020 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
ABAntoine Bertolotti
Antoine Bertolotti
ESE. Sbidian
E. Sbidian
OJO. Join‐Lambert
O. Join‐Lambert
IBI. Bourgault‐Villada
I. Bourgault‐Villada
MMM. Moyal‐Barracco
M. Moyal‐Barracco
TDThe Centre Of Evidence Of The French Society Of Dermatology
The Centre Of Evidence Of The French Society Of Dermatology
Hidradenitis suppurativa (HS) is a painful chronic inflammatory skin disease which impacts quality of life substantially. Its prevalence is estimated to 0.7%.1 Various pathophysiological hypotheses exist, but no therapeutic consensus, making the management of HS patients complex.

26 April 2021 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
AJAntoine Joubert
Antoine Joubert
FAFanny Andry
Fanny Andry
ABAntoine Bertolotti
Antoine Bertolotti
FAFrédéric Accot
Frédéric Accot
YKYatrika Koumar
Yatrika Koumar
CLCécile Levin
Cécile Levin
Background: As coronavirus 2019 (COVID-19) is spreading globally, several countries are handling dengue epidemics. As both infections are deemed to share similarities at presentation, it would be useful to distinguish COVID-19 from dengue in the context of co-epidemics. Hence, we performed a retrospective cohort study to identify predictors of both infections. Methodology/Principal findings: All the subjects suspected of COVID-19 between March 23 and May 10, 2020, were screened for COVID-19 within the testing center of the University hospital of Saint-Pierre, Reunion island. The screening consisted in a questionnaire surveyed in face-to-face, a nasopharyngeal swab specimen for the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) reverse transcription polymerase chain-reaction and a rapid diagnostic orientation test for dengue. Factors independently associated with COVID-19 or with dengue were sought using multinomial logistic regression models, taking other febrile illnesses (OFIs) as controls. Adjusted Odds ratios (OR) and 95% Confidence Intervals (95%CI) were assessed. Over a two-month study period, we diagnosed 80 COVID-19, 61 non-severe dengue and 872 OFIs cases eligible to multivariate analysis. Among these, we identified delayed presentation (>3 days) since symptom onset (Odds ratio 1.91, 95% confidence interval 1.07–3.39), contact with a COVID-19 positive case (OR 3.81, 95%CI 2.21–6.55) and anosmia (OR 7.80, 95%CI 4.20–14.49) as independent predictors of COVID-19, body ache (OR 6.17, 95%CI 2.69–14.14), headache (OR 5.03, 95%CI 1.88–13.44) and retro-orbital pain (OR 5.55, 95%CI 2.51–12.28) as independent predictors of dengue, while smoking was less likely observed with COVID-19 (OR 0.27, 95%CI 0.09–0.79) and upper respiratory tract infection symptoms were associated with OFIs. Conclusions/Significance: Although prone to potential biases, these data suggest that non-severe dengue may be more symptomatic than COVID-19 in a co-epidemic setting with higher dengue attack rates. At clinical presentation, nine basic clinical and epidemiological indicators may help to distinguish COVID-19 or dengue from each other and other febrile illnesses.

6 February 2020 in Dermatology and Therapy
Verified
Journal Article
Open access
PDF file
ABAntoine Bertolotti
Antoine Bertolotti
CFCyril Ferdynus
Cyril Ferdynus
BMBrigitte Milpied
Brigitte Milpied
NDNicolas Dupin
Nicolas Dupin
LHLaetitia Huiart
Laetitia Huiart
CDChristian Derancourt
Christian Derancourt
Introduction No hierarchy of first-line treatments for anogenital warts (AGWs) is provided in international guidelines. This study aimed to determine the efficacy of topical treatments and ablative procedures for the management of AGWs. Methods Twelve electronic databases were systematically searched from inception to August 2018. All randomized controlled trials (RCTs) comparing immunocompetent adults with AGWs who received at least 1 provider-administered or patient-administered treatment in at least 1 parallel group were included. Risk of bias assessment followed the Cochrane Handbook. The study endpoint was complete lesion response after clearance and recurrence assessment. A network meta-analysis was performed. Results A network geometry was constructed based on 49 of the 70 RCTs included in our systematic review. All but 4 RCTs had a high risk of bias. The most efficacious treatments compared to placebo were surgery (RR 10.54; CI 95% 4.53–24.52), ablative therapy + imiquimod (RR 7.52; CI 95% 4.53–24.52), and electrosurgery (RR 7.10; CI 95% 3.47–14.53). SUCRA values confirmed the superiority of surgery (90.9%), ablative therapy + imiquimod (79.8%), and electrosurgery (77.1%). The most efficacious patient-administered treatments were podophyllotoxin 0.5% solution (63.5%) and podophyllotoxin 0.5% cream (62.2%). Conclusions With low-level evidence of most included RCTs, surgery and electrosurgery were superior to other treatments after clearance and recurrence assessment. Podophyllotoxin 0.5% was the most efficacious patient-administered treatment. Combined therapies should be evaluated in future RCTs in view of their identified effectiveness. The results of future RCTs should systematically include clinical type, number and location of AGWs, and sex of the patient, to refine therapeutic indications. Protocol Registration PROSPERO-CRD42015025827

2 August 2023 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
DMDigé Mbu-Nyamsi
Digé Mbu-Nyamsi
MVMuriel Vincent
Muriel Vincent
MPMariane Perez-Fontana
Mariane Perez-Fontana
ABAnne-Laurence Best
Anne-Laurence Best
CMCharles Mesnard
Charles Mesnard
ABAntoine Bertolotti
Antoine Bertolotti
Introduction: Dengue is an arboviral disease transmitted by the dengue virus, whose vectors are Aedes aegypti and Aedes albopictus. The acute phase with its cohort of well-known symptoms is usually spontaneously favorable. Since 2020 in Reunion Island, a new symptom has appeared: the ocular damage of dengue fever, which has already been described in South Asia and South-East Asia. We therefore decided to describe the clinical, biological, ophthalmological, therapeutic, and outcomes of patients with ocular manifestations during dengue fever in Reunion Island in 2020. Patients and methods: This was a retrospective observational study. Patients were included from January 2020 to August 2020 and then reassessed by teleconsultation 1 year later. The patients were identified from the French public health surveillance network by all ophthalmologists on the island. Medical data were collected directly from medical records. Results: Twenty-eight patients were included. The mean age was 41.9 years. Ocular involvement occurred approximately 9.2 days after the onset of dengue symptoms. The main symptoms were scotoma (71.4%) and sudden decrease of visual acuity (39.2%). Eighteen patients (64.2%) had macular involvement. Fourteen patients were treated with oral or intravenous corticosteroids. Twenty-two (78.5%) patients were evaluated by telephone one year later. Scotoma and decreased visual acuity persisted in 15 patients. Thirteen patients (59%) were bothered by night driving, 32% of patients had reading difficulties and 27% of patients became sensitive to prolonged exposure to screens. Conclusion: Ocular complications of dengue require early and collegial management to limit the risk of long-term sequelae. Further studies on the characteristics and complications of dengue fever are needed to better understand this disease.